Major study tests new hope for inoperable liver cancer patients
NCT ID NCT07204327
Summary
This study looks back at the medical records of over 1,100 patients with advanced liver cancer that cannot be removed by surgery. It aims to see how well and how safely a standard drug combination (atezolizumab + bevacizumab) works when doctors also use various local treatments directly on the liver tumor. The main goal is to see if this combined approach helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.